预约演示
更新于：2025-07-20
Sodium Picosulfate Hydrate
匹可硫酸钠
更新于：2025-07-20
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1979-08-27), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H17NNa2O9S2 |
InChIKeyPUKNPYFKPBSERR-UHFFFAOYSA-N |
CAS号1307301-38-7 |
关联
41
项与 匹可硫酸钠 相关的临床试验CTRI/2025/03/083129
A Pilot study to Evaluate the Effectiveness and Safety of Combination of Milk of Magnesia, Liquid Paraffin, and Sodium Picosulfate Oral Emulsion for Treatment of Chronic Constipation in Patients with Comorbidities
CTRI/2024/07/070750
A Prospective, Multicentric Study, To Evaluate The Effectiveness And Safety Of Milk Of Magnesia+Liquid Paraffin+Sodium Picosulfate In The Treatment Of Constipation Symptoms In Post Ano-Rectal Surgical Patients - NA
ChiCTR2400081004
Comparison of Sodium Picosulfate/Magnesium Citrate Solution with Polyethylene Glycol Electrolyte Solution for Preoperative Bowel Preparation in Colonoscopy: A Single-Center, Randomized, Controlled Clinical Study
100 项与 匹可硫酸钠 相关的临床结果
登录后查看更多信息
100 项与 匹可硫酸钠 相关的转化医学
登录后查看更多信息
100 项与 匹可硫酸钠 相关的专利（医药）
登录后查看更多信息
263
项与 匹可硫酸钠 相关的文献（医药）2025-08-01BRAIN & DEVELOPMENT
Prevalence and management of gastrointestinal complications in Duchenne muscular dystrophy: A retrospective cohort study
Article
作者: Oba, Mari ; Takeshita, Eri ; Saito, Takashi ; Ito, Yusuke ; Sumitomo, Noriko ; Yamamoto, Kaoru ; Aihara, Yu ; Shimizu-Motohashi, Yuko ; Baba, Shimpei ; Komaki, Hirofumi ; Yamamoto, Hisako
BACKGROUND:
Gastrointestinal complications in Duchenne muscular dystrophy (DMD) have been understudied, particularly in Asian populations. This study aimed to determine the frequency and clinical characteristics of gastrointestinal complications.
METHODS:
This single-center, retrospective study reviewed medical records of 459 Asian patients with genetically or biopsy-confirmed DMD, aged 1-48 years, from September 1, 2010, to January 1, 2023.
RESULTS:
Constipation was the most common complication, affecting 149 patients (32.5 %), followed by dysphagia in 43 patients (9.4 %). Other conditions included irritable bowel syndrome in 8, gastroesophageal reflux disease in 7, hemorrhoids in 6, acute dilatation of stomach in 4, sigmoid colon volvulus in 2, and pneumatosis cystoides intestinalis in 2. Additionally, 1 case each of appendicitis, esophageal diverticulum, paralytic ileus, aerophagia, anal atresia, malabsorption syndrome, fecal incontinence, inflammatory bowel disease, gastrointestinal bleeding, and rectal prolapse was observed. Treatments for constipation included no intervention in 20 patients (13.4 %), sodium picosulfate hydrate in 62 (41.6 %), magnesium oxide in 59 (39.6 %), and polyethylene glycol 4000 in 20 (13.4 %). Logistic regression analysis showed that body mass index (BMI), age and angiotensin converting enzyme inhibitor use was significantly associated with constipation.
CONCLUSIONS:
This study highlighted constipation as the most frequent gastrointestinal complication in DMD and identified several rare but serious complications, offering key insights into real-world clinical practice.
2025-04-25Cureus Journal of Medical Science
Impact of Bowel Preparation Type on Colonoscopy Quality and Adenoma Detection: A Comparative Study
Article
作者: Yeap, Elaine ; Maramraj, Sankeerthan
Background Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Colonoscopy is the gold standard for CRC screening, but its effectiveness depends on bowel preparation quality. This study compares polyethylene glycol (PEG)-based MoviPrep (Norgine Limited, Hengoed, UK) and sodium picosulfate-based Picolax (Ferring GmbH, Kiel, Germany) in terms of bowel cleansing quality, caecal and ileal intubation rates, and adenoma detection rate (ADR). Methods This retrospective observational study analysed 6,921 colonoscopies performed at University Hospital Crosshouse between June 2020 and June 2023. Bowel preparation quality was assessed using the modified Ottawa Bowel Preparation Scale, categorised as Excellent, Good, Fair, or Inadequate. ADR was determined by histologically confirmed adenomas. Statistical comparisons between the two groups were performed using chi-square tests. Results MoviPrep was used in 6,219 (89.9%) of cases, while Picolax was used in 702 (10.1%) cases. MoviPrep was associated with a lower inadequate preparation rate (343 (5.5%) vs. 63 (9.0%)), a higher caecal intubation rate (3,675 (59.1%) vs. 307 (43.7%)) and ileal intubation rate (1,119 (18.0%) vs. 81 (11.5%)), and a higher ADR (2,295 (36.9%) vs. 167 (23.8%)). Conclusion MoviPrep demonstrated superior bowel cleansing, higher completion rates, and greater adenoma detection, supporting its use as a preferred bowel preparation method for colonoscopy in clinical practice.
2025-04-01TALANTA
A smartphone-based dual-modal lateral flow immunochromatographic assay for multiplex detection of illegal stimulant laxatives in slimming foods
Article
作者: Chen, Sha ; Lei, Hongtao ; Chen, Jiahong ; Xu, Zhenlin ; Liang, Shuiyuan ; Guan, Tian
Stimulant laxatives (especially bisacodyl and sodium picosulfate) are frequently found to be adulterated into slimming foods, causing health-threatening effects to consumers. Sensitive, accurate, easy-to-operate and portable multiplex analytical techniques are still desired for the rapid screening of stimulant laxatives in slimming foods. In this work, a highly sensitive dual-modal colorimetric/photothermal lateral flow immunochromatographic assay (LFIA) was established based on facilely prepared concentrated gold nanoparticles (cAuNPs). Due to the enhanced local surface plasmon resonance and absorption intensity of our unique cAuNPs, this LFIA can simultaneously detect bisacodyl, bis-(p-hydroxyphenyl)-pyridyl-2-methane and sodium picosulfate in slimming food as low as 0.014-0.308 ng/mL by a smartphone-based photothermal device or 1.4-10 ng/mL by naked eyes. Compared with traditional AuNPs-LFIA, it demonstrated 8.48-10.27 times higher sensitivity in photothermal mode. Moreover, in the recovery test and blind sample analysis, this dual-modal LFIA exhibited reasonable recoveries (85.04 %-119.18 %) and high correlation with authorized LC-MS/MS method, suggesting high accuracy and applicability. This work offers a highly sensitive, accurate and convenient way for the on-site determination of stimulant laxatives, which can also be employed to detect other food hazards, environmental pollutants, or clinical analytes within a few minutes.
100 项与 匹可硫酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 造影剂 | 日本 | 1992-07-01 | |
| 肠道准备 | 日本 | 1992-03-27 | |
| 便秘 | 日本 | 1979-08-27 | |
| 便秘 | 日本 | 1979-08-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胃肠道疾病 | 临床3期 | 法国 | 2014-11-01 | |
| 胃肠道疾病 | 临床3期 | 德国 | 2014-11-01 | |
| 胃肠道疾病 | 临床3期 | 荷兰 | 2014-11-01 | |
| 弥漫性大B细胞淋巴瘤 | 临床3期 | 日本 | 2014-09-01 | |
| 功能性便秘 | 临床3期 | 中国 | 2011-09-16 | |
| 药用辅料 | 临床3期 | 美国 | 2010-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 窪餘獵餘醖衊蓋製鏇夢(構齋齋壓築觸簾獵襯鏇) = 蓋觸獵醖齋憲夢鬱鹹遞 膚艱選築齋廠鏇構淵醖 (襯獵鬱積夢糧壓憲範壓 ) | - | 2014-10-01 | ||
Polyethylene Glycol (PEG) | 窪餘獵餘醖衊蓋製鏇夢(構齋齋壓築觸簾獵襯鏇) = 製遞窪憲艱夢鬱築淵築 膚艱選築齋廠鏇構淵醖 (襯獵鬱積夢糧壓憲範壓 ) | ||||||
临床4期 | - | 862 | Standard dosing | 夢獵範觸範衊築鹹憲構(憲壓鹽遞鬱糧鹹窪觸觸) = 襯壓製糧窪餘範艱憲遞 選築遞蓋網夢廠蓋鏇膚 (鹹積積糧膚築餘鹹齋範 ) | - | 2014-08-01 | |
Split dosing | 夢獵範觸範衊築鹹憲構(憲壓鹽遞鬱糧鹹窪觸觸) = 網襯簾簾膚蓋鹹蓋獵構 選築遞蓋網夢廠蓋鏇膚 (鹹積積糧膚築餘鹹齋範 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用